IN THIS ISSUE:

Research and Development to Improve Reproductive Health

From Bench to Bedroom: Biomedical Research at the Population Council

Male Contraception in Discovery

Multipurpose Prevention Technologies in Early-Stage Development

Contraceptive Vaginal Rings in Late-Stage Development

Delivering on a Promise: The International Contraceptive Access (ICA) Foundation

Profiles: José Fernández Romero, Scientist at the Council’s Center For Biomedical Research, and Barbara Ebert, Council Donor
1 OUT OF EVERY 4 WOMEN in low- and middle-income countries want to delay or prevent pregnancy but are not using a modern contraceptive method. New prevention options aimed at reducing unintended pregnancy and the transmission of HIV and other STIs are urgently needed. The Population Council is meeting this challenge by developing new technologies and products to help people enhance their health and wellbeing.

EVERY DAY NEARLY 6,300 PEOPLE become infected with HIV, disproportionately affecting young women aged 15-24 in pandemic regions.

EVERY DAY MORE THAN 1 MILLION PEOPLE contract sexually transmitted infections (STIs) that can cause:

- Cancer
- Infertility
- Pregnancy complications
- Increased HIV risk

SOURCES:
RESEARCH AND DEVELOPMENT TO IMPROVE REPRODUCTIVE HEALTH

by Julia Bunting

Since it was founded in 1956, the Population Council’s Center for Biomedical Research (CBR) has specialized in researching and developing drugs, technologies, and products that enable women, men, and young people to protect and enhance their reproductive health and wellbeing. Hundreds of millions of women have used a family planning method developed by the Council, including the Copper T IUD, the Mirena® intrauterine system, the implants Norplant® and Jadelle®, and the progesterone contraceptive vaginal ring for breastfeeding women. Since the beginning of the HIV epidemic in the 1980s, the Council has also conducted research to identify new, user-controlled methods to prevent HIV infection.

Today, Council scientists at CBR are researching new technologies—rings, gels, and other systems—to provide even greater contraceptive choice as well as protection from HIV and other sexually transmitted infections. My colleagues identify leads for new products, develop the most promising ideas through years of research, work with regulatory authorities to secure approval for these technologies, and collaborate with pharmaceutical companies, governments, and a host of other partners to bring these products to market. This work is literally improving the lives of millions of people around the world today and the benefits of these investments will continue for generations to come.

In this issue of Momentum you will read about the Council’s rich and distinguished history of biomedical research and the significant impact of this work on women’s reproductive health (page 4). You will see how the Council continues to be at the cutting edge of developing new contraceptive vaginal rings (page 10), as well as the Council’s work to expand access to long-acting reversible contraception (page 12). Council researchers are also exploring innovative contraceptive methods for men (page 6), and multipurpose prevention technologies to protect against various sexual and reproductive health risks (page 8). You will meet Council scientist José Fernández Romero, who is identifying new ways to prevent HIV and other sexually transmitted infections (page 14), and Barbara Ebert, a decades-long supporter of the Council’s work to develop new contraceptive methods (page 15).

I am deeply honored to have joined the Population Council, and I am committed to building on our strong legacy and investing in a bright future of biomedical research.

Together we will continue to provide women, men, and young people around the world with new products to safeguard their wellbeing and help them live more productive, healthier lives.

Thank you for your support.
In 1956 the Population Council established one of the first laboratories dedicated to the research and development of new technologies to protect reproductive health.

Today CBR is a vibrant hub of R&D on the campus of Rockefeller University in New York City—and the need for new sexual and reproductive health technologies is just as urgent now as it was nearly 60 years ago. The R&D process is long and complex, particularly when products are being developed for low-resource settings where diverse needs and challenges must be addressed. Council discoveries have led to identifying potential added health benefits of several products in the pipeline, such as protective effects of novel contraceptive hormones on breast and prostate health. Basic science research at CBR has also opened doors to exploring new treatments for chronic conditions such as uterine fibroids and multiple sclerosis.

The Council proudly invests in the full R&D lifecycle, taking a “bench to bedroom” approach that focuses on end-users from the start and works with partners to identify and fill product niches that are otherwise not profitable for traditional biotechnology or pharmaceutical companies. The Council’s R&D efforts lead to safe and effective products that are acceptable, accessible, and designed to meet people’s varying sexual and reproductive health needs at different points in their lives.
MALE CONTRACEPTION IN DISCOVERY

Researchers at the Population Council are developing a one-year hormonal contraceptive implant for men containing the novel androgen MENT®.

THE PROBLEM  There is a recognized need for long-acting reversible contraception (LARC) for men, but as yet there are no available methods. Studies suggest that women and men would enthusiastically welcome additional male contraceptive choices, which would enable men to better share the responsibility, risks, and costs of family planning. The male reproductive system offers several potential targets for both hormonal and non-hormonal contraception; however, many challenges exist including the necessity of stopping daily production of millions of sperm. A safe, effective, acceptable male LARC requires an approach that will reduce sperm count without daily use.

THE PROGRESS  Through the development of MENT® from a synthetic steroid that resembles testosterone, researchers have discovered that administering an androgen (a male sex hormone) in combination with a synthetic progestin (another hormone) can reduce sperm count without impairing a man’s sex drive. The Council tested this approach in early clinical studies, which showed promising results by inhibiting sperm production using four MENT implants in healthy men. The next step will be a randomized study to evaluate the safety and efficacy of MENT, either alone or in conjunction with the injectable progestin known as DMPA (Depo-Provera®), to determine whether the combination of MENT and a synthetic progestin reduces sperm count more quickly and effectively.

THE IMPACT  New, effective options for male contraception would expand the mix of available family planning methods. Among men who reported being interested in using male contraception, 30% said they would prefer implants. Unlike testosterone, MENT does not enlarge the prostate; and because of its high potency, a low daily dose can be administered, making delivery through an implant system preferable for long-term use. Discovery of the second active component will take the MENT implant technology one step closer to becoming a viable LARC option for men.

PARTNERS  Bayer Schering Healthcare; Christina Wang (David Geffen School of Medicine, University of California, Los Angeles); Crystal Pharma; David T. Baird (U.K. Medical Research Council [MRC] Centre for Reproductive Health at the University of Edinburgh [formerly the MRC Reproductive Biology Unit]); Eberhard Nieschlag (Center for Reproductive Medicine and Andrology of the University Hospital of Munster, Germany); Horacio Croxatto (Instituto Chileno de Medicina Reproductiva [ICMER], Santiago, Chile); Richard Anderson (U.K. MRC Centre for Reproductive Health at the University of Edinburgh)

DONORS  U.S. National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; The George J. Hecht Fund; The Lita Annenberg Hazen Foundation; The William and Flora Hewlett Foundation; Population Council
occurring algae protein shown to be safe and highly effective against HI in the lab and against HSV-2 and HPV in preclinical studies. A griffithsin gel is being tested to help develop a sustained-release vaginal ring and a nanofiber delivery system (a film-like formulation) to provide protection at the time of sex. The first human studies of griffithsin vaginal gel are expected to begin in 2016.

THE IMPACT If proven effective, these MPTs could contribute substantially to global health. MZC-based products could increase protection against HIV and HSV-2 at lower doses, which in turn could improve product safety, decrease chances of drug resistance, and reduce costs. Non-ARV-based MPT products (e.g., those containing ZC or griffithsin) could help to reduce the emergence of drug-resistant HIV types, eliminate the need for HIV screening prior to use, and potentially be provided over-the-counter. Council researchers are working with academic, nonprofit, and industry experts to advance promising candidates through the pipeline and to identify strategies for introduction and scale-up to ensure that MPTs, once available, are accessible to those most in need.

COLLABORATORS Duke University; Fraunhofer Center for Molecular Biotechnology; ProMed Pharma; Tulane National Primate Research Center; University of Alabama at Birmingham; University of Washington

DONORS U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases; U.S. President’s Emergency Plan for AIDS Relief (PEPFAR); United States Agency for International Development (USAID); Sweden Ministry for Foreign Affairs

THE PROBLEM Male and female condoms are currently the only available products designed to provide concurrent protection against pregnancy and sexually transmitted infections (STIs), including HIV. Condoms are effective when used correctly, but there are many barriers to use and they are not practical for women and couples who want to have children. New products are needed to address the needs of women and men at risk for STIs, HIV, and unintended pregnancy.

THE PROGRESS The Population Council has long-acting vaginal rings and on-demand multipurpose prevention technologies (MPTs) in varying stages of development. Several candidates contain a combination of MIV-150 (M), an antiretroviral (ARV) drug that prevents HIV from infecting target cells; zinc acetate (Z), an antiviral agent with activity against HIV and genital herpes simplex virus (HSV-2); and carrageenan (C), a seaweed-derived compound active against human papillomavirus (HPV). The MZC vaginal ring is designed to prevent HIV and other STIs for 90 days; the MZCL ring offers these same potential benefits and adds the contraceptive levonorgestrel (L) to prevent pregnancy. The Council has produced and tested prototype rings in preclinical and animal studies with promising results and recently completed a Phase I clinical safety trial of an MZC vaginal gel. A non-ARV ZC gel has also been found to be safe and active against HIV, HPV, and HSV-2 in preclinical studies. Products are also being developed with griffithsin, a naturally occurring algae protein shown to be safe and highly effective against HIV in the lab and against HSV-2 and HPV in preclinical studies. A griffithsin gel is being tested to help develop a sustained-release vaginal ring and a nanofiber delivery system (a film-like formulation) to provide protection at the time of sex. The first human studies of griffithsin vaginal gel are expected to begin in 2016.

THE IMPACT If proven effective, these MPTs could contribute substantially to global health. MZC-based products could increase protection against HIV and HSV-2 at lower doses, which in turn could improve product safety, decrease chances of drug resistance, and reduce costs. Non-ARV-based MPT products (e.g., those containing ZC or griffithsin) could help to reduce the emergence of drug-resistant HIV types, eliminate the need for HIV screening prior to use, and potentially be provided over-the-counter. Council researchers are working with academic, nonprofit, and industry experts to advance promising candidates through the pipeline and to identify strategies for introduction and scale-up to ensure that MPTs, once available, are accessible to those most in need.

COLLABORATORS Duke University; Fraunhofer Center for Molecular Biotechnology; ProMed Pharma; Tulane National Primate Research Center; University of Alabama at Birmingham; University of Washington

DONORS U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases; U.S. President’s Emergency Plan for AIDS Relief (PEPFAR); United States Agency for International Development (USAID); Sweden Ministry for Foreign Affairs

THE PROBLEM Male and female condoms are currently the only available products designed to provide concurrent protection against pregnancy and sexually transmitted infections (STIs), including HIV. Condoms are effective when used correctly, but there are many barriers to use and they are not practical for women and couples who want to have children. New products are needed to address the needs of women and men at risk for STIs, HIV, and unintended pregnancy.

THE PROGRESS The Population Council has long-acting vaginal rings and on-demand multipurpose prevention technologies (MPTs) in varying stages of development. Several candidates contain a combination of MIV-150 (M), an antiretroviral (ARV) drug that prevents HIV from infecting target cells; zinc acetate (Z), an antiviral agent with activity against HIV and genital herpes simplex virus (HSV-2); and carrageenan (C), a seaweed-derived compound active against human papillomavirus (HPV). The MZC vaginal ring is designed to prevent HIV and other STIs for 90 days; the MZCL ring offers these same potential benefits and adds the contraceptive levonorgestrel (L) to prevent pregnancy. The Council has produced and tested prototype rings in preclinical and animal studies with promising results and recently completed a Phase I clinical safety trial of an MZC vaginal gel. A non-ARV ZC gel has also been found to be safe and active against HIV, HPV, and HSV-2 in preclinical studies. Products are also being developed with griffithsin, a naturally occurring algae protein shown to be safe and highly effective against HIV in the lab and against HSV-2 and HPV in preclinical studies. A griffithsin gel is being tested to help develop a sustained-release vaginal ring and a nanofiber delivery system (a film-like formulation) to provide protection at the time of sex. The first human studies of griffithsin vaginal gel are expected to begin in 2016.

THE IMPACT If proven effective, these MPTs could contribute substantially to global health. MZC-based products could increase protection against HIV and HSV-2 at lower doses, which in turn could improve product safety, decrease chances of drug resistance, and reduce costs. Non-ARV-based MPT products (e.g., those containing ZC or griffithsin) could help to reduce the emergence of drug-resistant HIV types, eliminate the need for HIV screening prior to use, and potentially be provided over-the-counter. Council researchers are working with academic, nonprofit, and industry experts to advance promising candidates through the pipeline and to identify strategies for introduction and scale-up to ensure that MPTs, once available, are accessible to those most in need.

COLLABORATORS Duke University; Fraunhofer Center for Molecular Biotechnology; ProMed Pharma; Tulane National Primate Research Center; University of Alabama at Birmingham; University of Washington

DONORS U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases; U.S. President’s Emergency Plan for AIDS Relief (PEPFAR); United States Agency for International Development (USAID); Sweden Ministry for Foreign Affairs

THE PROBLEM Male and female condoms are currently the only available products designed to provide concurrent protection against pregnancy and sexually transmitted infections (STIs), including HIV. Condoms are effective when used correctly, but there are many barriers to use and they are not practical for women and couples who want to have children. New products are needed to address the needs of women and men at risk for STIs, HIV, and unintended pregnancy.

THE PROGRESS The Population Council has long-acting vaginal rings and on-demand multipurpose prevention technologies (MPTs) in varying stages of development. Several candidates contain a combination of MIV-150 (M), an antiretroviral (ARV) drug that prevents HIV from infecting target cells; zinc acetate (Z), an antiviral agent with activity against HIV and genital herpes simplex virus (HSV-2); and carrageenan (C), a seaweed-derived compound active against human papillomavirus (HPV). The MZC vaginal ring is designed to prevent HIV and other STIs for 90 days; the MZCL ring offers these same potential benefits and adds the contraceptive levonorgestrel (L) to prevent pregnancy. The Council has produced and tested prototype rings in preclinical and animal studies with promising results and recently completed a Phase I clinical safety trial of an MZC vaginal gel. A non-ARV ZC gel has also been found to be safe and active against HIV, HPV, and HSV-2 in preclinical studies. Products are also being developed with griffithsin, a naturally occurring algae protein shown to be safe and highly effective against HIV in the lab and against HSV-2 and HPV in preclinical studies. A griffithsin gel is being tested to help develop a sustained-release vaginal ring and a nanofiber delivery system (a film-like formulation) to provide protection at the time of sex. The first human studies of griffithsin vaginal gel are expected to begin in 2016.

THE IMPACT If proven effective, these MPTs could contribute substantially to global health. MZC-based products could increase protection against HIV and HSV-2 at lower doses, which in turn could improve product safety, decrease chances of drug resistance, and reduce costs. Non-ARV-based MPT products (e.g., those containing ZC or griffithsin) could help to reduce the emergence of drug-resistant HIV types, eliminate the need for HIV screening prior to use, and potentially be provided over-the-counter. Council researchers are working with academic, nonprofit, and industry experts to advance promising candidates through the pipeline and to identify strategies for introduction and scale-up to ensure that MPTs, once available, are accessible to those most in need.

COLLABORATORS Duke University; Fraunhofer Center for Molecular Biotechnology; ProMed Pharma; Tulane National Primate Research Center; University of Alabama at Birmingham; University of Washington

DONORS U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases; U.S. President’s Emergency Plan for AIDS Relief (PEPFAR); United States Agency for International Development (USAID); Sweden Ministry for Foreign Affairs
The Population Council has developed two innovative contraceptive vaginal rings to meet women’s varying family planning needs: a three-month ring that contains progesterone for use by breastfeeding women, and an investigational one-year ring that can prevent pregnancy for a full year.

THE PROBLEM  Women in low-resource settings face unique barriers to obtaining effective contraception, including limited access to different options and a lack of trained health professionals to provide services or counseling. In addition, although exclusive breastfeeding may prevent pregnancy for the first six months after childbirth, return to fertility can occur sooner than anticipated, leaving women at risk for unintended pregnancy, unsafe abortion, and poor health outcomes. There is an urgent need for convenient new contraceptive methods that are safe, effective, easy to use, and under a woman’s control.

THE PROGRESS  The Council’s three-month progesterone vaginal ring (PVR) can be used safely by breastfeeding women to help space pregnancies. It does not affect lactation and does not require insertion by a healthcare provider. Each PVR can be used continuously for three months, and rings can be used successively for up to a year. Fertility returns shortly after removal. The ring has been available in Latin America since 1998 under the brand name Progering®. The Council is working to introduce the PVR in more countries where prolonged lactation is vital for infant health—and where access to highly effective contraceptives is limited.

The one-year ring prevents pregnancy by releasing a low dose of ethinyl estradiol (EE), an approved, marketed hormonal product, and Nestorone® (NES), an investigational progestin that has been shown to be highly effective in preventing ovulation. The NES/EE ring is inserted by the woman, left in place for 21 days, and removed for 7 days. One ring can be used for up to 13 cycles (one year), and fertility returns after discontinuing use. The Council is preparing to submit a New Drug Application to the US Food and Drug Administration and will seek to introduce the one-year NES/EE ring in various settings, including in low- and middle-income countries.

THE IMPACT  The PVR is currently available to women in Bolivia, Chile, Colombia, Dominican Republic, Ecuador, Guatemala, Honduras, and Peru, and the market is now expanding to include regulatory applications in Brazil and Mexico. The Council is also working toward product introduction in India, Kenya, Nigeria, and Senegal, with the goal of expanding to other countries. The Council’s one-year NES/EE ring, if approved by the FDA, would be a unique long-acting reversible contraceptive that is effective for 13 cycles, is under the woman’s control, and does not require insertion or removal by a trained healthcare provider.

PARTNERS  Bill & Melinda Gates Institute for Population and Reproductive Health; Grünenthal (formerly Andromaco); International Committee for Contraception Research; Ministries of Health of India, Kenya, Nigeria, and Senegal; QPharma; WomenCare Global; World Health Organization

DONORS  Barrus Foundation; Bill & Melinda Gates Foundation; U.S. Agency for International Development; U.S. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development Contraceptive Clinical Trials Network
The International Contraceptive Access (ICA) Foundation, a public–private partnership between the Population Council and Bayer OY, is helping expand access to long-acting reversible contraception in low-resource settings.

**THE PROBLEM**

The levonorgestrel intrauterine system (LNG IUS) provides up to five years of safe, effective, and continuous contraception. Developed by the Population Council and Finland-based Bayer OY, the LNG IUS is distributed by Bayer HealthCare Pharmaceuticals in the private market under the trade name Mirena® in more than 120 countries. In low-resource settings, the LNG IUS is often inaccessible due to financial barriers and supply chain challenges.

**THE PROGRESS**

The ICA Foundation was established in 2003 to help overcome these obstacles by making the LNG IUS available at no cost in resource-poor settings. To date, the Foundation has provided over 67,000 LNG IUS and training materials to projects in 28 low- and middle-income countries. To become a project of the Foundation, eligible organizations must submit an application describing their plans for integrating the LNG IUS into their reproductive health service delivery activities. This local responsibility ensures that the donated LNG IUS are distributed in a culturally-appropriate and acceptable manner.

**THE IMPACT**

Two of the ICA Foundation’s most successful projects are highlighted here to illustrate the impact of this important work.

**BRAZIL:** Since becoming an ICA Foundation project in 2006, the Center for Research in Reproductive Health of Campinas (CEMICAMP) and the University of Campinas School of Medicine’s Department of Obstetrics and Gynecology (UNICAMP) has provided an average of 271 women per month with free LNG IUS insertions at more than 20 sites throughout Brazil. It is the Foundation’s largest project, having received nearly 21% of all LNG IUS donations made in the past decade (over 14,000 devices) and trained nearly 100 health professionals across Brazil on counseling and insertion/removal techniques. The project is led by Prof. Dr. Luis Bahamondes, an eminent OB/GYN based in Campinas.

**NIGERIA:** With 35 sites across Nigeria, Rotary International has received 7,500 LNG IUS donations since becoming an ICA Foundation project in 2007. Local partners have developed and implemented health provider education and community outreach activities involving men and religious leaders in family planning promotion, and women served by project sites report very high acceptance of the LNG IUS. The project is led by Robert Zinser, Chief Executive Officer of the Rotarian Action Group for Population and Development and a long-standing champion for maternal health and family planning.

**DONORS**

Bayer HealthCare Pharmaceuticals, Population Council
Tell us about the work you do.
I lead the preclinical virology group in the microbicides laboratory at CBR. We conduct research to identify compounds that might be active against HIV and other sexually transmitted pathogens such as genital herpes simplex virus (HSV-2) and human papillomavirus (HPV). After one or more compounds has been formulated as a product candidate (for example, as you read about on page 8) and before any human testing is done, we conduct rigorous studies on these microbicide and multipurpose prevention technology (MPT) candidates to ensure they are safe and effective. These preclinical studies are necessary in order to identify the most promising microbicide and MPT candidates to be further developed and tested in people.

Why did you choose to do this work at the Council?
The Population Council has a rich history of improving the lives and expectations of millions of people. Our HIV prevention program follows the same philosophy of empowering the world’s most vulnerable by working to make user-controlled microbicides and MPTs a reality.

What led you to enter the field of biomedical research?
My passion for virology started 20 years ago when I began studying microbiology. This was back in the 1990s, when people began paying more attention to the global impact of HIV and AIDS. After I received my bachelors degree in microbiology at the University of Havana, I stayed to teach virology and genetic engineering while conducting research on indigenous plants and their potential for antiviral activity. Soon after I arrived in the US from Cuba, the Council introduced me to the new idea of HIV prevention through microbicides, and I decided to use my expertise in virology to serve the microbicide research community. Today my goal is to help develop potential MPTs that protect women and men not only from HIV but also other sexually transmitted infections (STIs) and unintended pregnancy.

What has been most rewarding for you in your career?
I have enjoyed helping build a team with the unique expertise to test potential products against three major, non-curable viral STIs. I am lucky to work with colleagues who understand the importance of teamwork and are passionate about the work we do. I also teach biology and microbiology at Hostos Community College in the Bronx—a gratifying experience for me, especially when some of my students, many of whom are minorities, decide to pursue a career in biology. I hope that by teaching at Hostos, I can make a modest contribution to raise the profile of minorities in the sciences.

I give to the Population Council because of the long association my late husband, Dr. Robert Ebert, had with the organization—30 years as a board member, 10 years as chair. He considered the Population Council one of the most important and effective organizations he had the privilege of serving.

Bob spent his career in academic medicine—as bench scientist, clinician, and medical school dean. He worked on new drugs to treat tuberculosis and was continually challenged to translate his research to the bedside as quickly as possible. He saw how new drugs improved people’s lives. He cared deeply about public health issues, including efficient and cost-effective delivery of medical care to needy populations, prevention of communicable diseases, and family planning. Becoming a trustee of the Population Council extended his interest in public health to the global level. He became even more committed to developing new products and initiatives to improve the reproductive health of women in developing nations.

It was my privilege and good fortune to accompany him on some board meetings in Africa. One took us to Senegal and Mali, where we visited clinics for and managed by women. These women stressed the importance of good health, prenatal care, and family planning. When we arrived at one clinic, the clients, having been told that Population Council Trustees were coming to visit, were waiting for us all dressed up. They passed their babies to us to hold and coo over (in fractured French for most of us). They used theater to illustrate the important health issues they faced; we saw two skits in which women impressed upon their husbands the importance of family planning. They played these parts with a good deal of humor—including an irate mother who browbeat her son for getting his wife pregnant again—and were very effective in putting their point across.

While I make modest gifts to other family planning organizations, I am particularly impressed with the broad scope of the Council’s influence throughout the world. Family planning is obviously one, but the work of the Center for Biomedical Research in developing safe, innovative, and affordable contraceptives has made a huge impact in this area. Addressing other issues such as HIV prevention, education and safe spaces for girls, and poverty alleviation makes the Population Council stand out as a leader.
WITH YOUR HELP, WE CAN CONTINUE TO PROVIDE PEOPLE WITH NEW PRODUCTS TO SAFEGUARD THEIR REPRODUCTIVE HEALTH AND WELLBEING.

Support the Population Council: 
popcouncil.org/supporting

Sign up for the Council’s e-mail list: 
popcouncil.org
(Click “Subscribe” on the homepage)
The Population Council confronts critical health and development issues—from stopping the spread of HIV to improving reproductive health and ensuring that young people lead full and productive lives. Through biomedical, social science, and public health research in 50 countries, we work with our partners to deliver solutions that lead to more effective policies, programs, and technologies that improve lives around the world. Established in 1952 and headquartered in New York, the Council is a nongovernmental, nonprofit organization governed by an international board of trustees.

Photo credits: page ii: Dennis Van Der Walle; page 6: Gavra Sinha; page 8: Lajos Rapasi; page 12: Evelyn Castle; all others by Population Council staff.

To receive e-mail announcements about new Council resources and information, click the “Subscribe” button on our homepage: popcouncil.org

For additional information, contact: development@popcouncil.org
877-339-0500

© 2015 The Population Council, Inc.
Printed on recycled paper.